Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator

Fig. 3

Cardiac diastolic (panel A, C) and systolic (panel E) cardiac function during pharmacologically induced chronotropic stress and acute pharmacological reduction of plasma FAs with acipimox before (PE and PI) and during treatments (E and I). Change in diastolic (panels B, D) and systolic (panel F) cardiac function between treatments (ΔT) or between treatment and washout (ΔE and ΔI). Data are Mean ± SEM. *p < 0.05. ‡‡p < 0.01 vs MR Day 1. LVPFR Left ventricular peak filling rate, LAPEF Left atrial passive emptying fraction, LVEF Left ventricular emptying fraction

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840